Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249327 | 0.89 | MAPK9 (0.51) | MAPK9MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3253883 | 0.84 | MAPK9 (0.47) | MAPK9MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13678697 | 0.82 | MAPK9 (0.49) | MAPK9MAPK14 | |
| SCHEMBL13678720 | 0.80 | MAPK9 (0.56) | MAPK9MAPK14 | |
| SCHEMBL3246016 | 0.80 | MAPK9 (0.48) | MAPK9MAPK14 | |
| SCHEMBL3246009 | 0.80 | MAPK9 (0.48) | MAPK9MAPK14 | |
| SCHEMBL3252013 | 0.78 | MAPK9 (0.46) | MAPK9MAPK14 | |
| SCHEMBL3246204 | 0.77 | MAPK14 (0.47) | MAPK9MAPK14 | |
| SCHEMBL3257122 | 0.77 | MAPK9 (0.76) | MAPK9MAPK14 | |
| SCHEMBL3249333 | 0.77 | MAPK14 (0.55) | MAPK9MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833477-B1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2010-06-02 | — | — | EP | claimed |
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | IL1R1, IL1A, IL1B | MAPK9 2483/4885MAPK14 2463/4885NPC1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.